BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Braks RE, Ganne-Carrié N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13(42): 5648-5653 [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648]
URL: https://www.wjgnet.com/1948-5182/full/v13/i42/5648.htm
Number Citing Articles
1
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionExpert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
2
Angelo Iacobellis, Angelo Andriulli. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infectionExpert Opinion on Pharmacotherapy 2009; 10(12): 1929 doi: 10.1517/14656560903066811
3
N. Jung, W.-J. Mayet, P.R. Mertens, J. Meyer (federführend), O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss, C.-M. Wendtner. Rationelle Diagnostik und Therapie in der Inneren Medizin2020; : pA-1 doi: 10.1016/B978-3-437-06282-7.50008-5
4
Vivian Ng, Sammy Saab. Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis CClinical Gastroenterology and Hepatology 2011; 9(11): 923 doi: 10.1016/j.cgh.2011.05.028
5
Norberto C. Chávez-Tapia, Ezequiel Ridruejo, Angelo Alves de Mattos, Fernando Bessone, Jorge Daruich, Juan F. Sánchez-Ávila, Hugo Cheinquer, Rodrigo Zapata, Misael Uribe, Francisco Bosques-Padilla, Adrián Gadano, Alejandro Soza, Milagros Dávalos-Moscol, Claudio Marroni, Linda Muñoz-Espinoza, Graciela Castro-Narro, Raymundo Paraná, Nahum Méndez-Sánchez. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the LiverAnnals of Hepatology 2013; 12: S3 doi: 10.1016/S1665-2681(19)31404-8
6
Lars Haukali Omland, Peter Jepsen, Henrik Krarup, Peer Brehm Christensen, Nina Weis, Lars Nielsen, Niels Obel, Henrik Toft Sørensen, Sherri Oliver Stuver. Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: Results from the DANVIR cohort studyInternational Journal of Cancer 2012; 130(10): 2310 doi: 10.1002/ijc.26283
7
Nahum Méndez-Sánchez, Adrian Gadano, Angelo Alves de Mattos, Alejandro Soza, Augusto Marroni Claudio, Marcela Galoppo, David Kershenobich, Edna Strauss, Eduardo Fassio, Gilberto Castañeda, Guillermo Valladares, Henrique Sergio Moraes Coelho, Jorge Daruich, Miguel Garassini, Milagros Dávalos, Misael Uribe, Maribel Rodriguez-Torres, Rodrigo Zapata, Marco Arrese, Francisco Sánchez-Ávila, Margarita Dehesa, Francisco Bosques Padilla, Paulo Roberto Lerias de Almeida, Mario Pessoa, Rocío Torres-Ibarra, Francisco Hevia, Miguel Contreras, Hugo Cheinquer. Latin American Association for the Study of the Liver Practice GuidelinesAnnals of Hepatology 2010; 9: S8 doi: 10.1016/S1665-2681(19)31718-1
8
Amit G Singal, Purva Gopal, Adam C Yopp. Radiation Therapy for Liver Tumors2017; : 149 doi: 10.1007/978-3-319-54531-8_13
9
Alajos Pár. Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinomaOrvosi Hetilap 2009; 150(1): 19 doi: 10.1556/oh.2009.28529
10
Nancy McGreal, Donald M. Jensen. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cureLiver International 2009; 29(4): 481 doi: 10.1111/j.1478-3231.2009.02000.x
11
Joseph Ahn, Steven L. Flamm. Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatmentCurrent Hepatitis Reports 2009; 8(2): 59 doi: 10.1007/s11901-009-0009-7
12
Kelly Fernanda Nomura DRESCH, Angelo Alves de MATTOS, Cristiane Valle TOVO, Fernanda Quadros de ONOFRIO, Leandro CASAGRANDE, Alberi Adolfo FELTRIN, Iago Christofoli de BARROS, Paulo Roberto Lerias de ALMEIDA. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUSRevista do Instituto de Medicina Tropical de São Paulo 2016; 58(0) doi: 10.1590/S1678-9946201658037
13
N. Merchante, M. Rodríguez-Fernández, J. A. Pineda. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and ControversiesCurrent HIV/AIDS Reports 2020; 17(1): 6 doi: 10.1007/s11904-019-00475-0
14
Bryony Simmons, Jawaad Saleem, Katherine Heath, Graham S. Cooke, Andrew Hill. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological ResponseClinical Infectious Diseases 2015; 61(5): 730 doi: 10.1093/cid/civ396
15
Vincent Mallet, Hélène Gilgenkrantz, Jeanne Serpaggi, Virginie Verkarre, Anaïs Vallet-Pichard, Hélène Fontaine, Stanislas Pol. Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis CAnnals of Internal Medicine 2008; 149(6): 399 doi: 10.7326/0003-4819-149-6-200809160-00006
16
Nicolás Merchante, Esperanza Merino, Francisco Rodríguez-Arrondo, Cristina Tural, Josefa Muñoz, Marcial Delgado-Fernández, Francisco Jover, Maria J. Galindo, Antonio Rivero, José López-Aldeguer, Koldo Aguirrebengoa, Alberto Romero-Palacios, Eduardo Martínez, Juan A. Pineda. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinomaAIDS 2014; 28(1): 41 doi: 10.1097/QAD.0000000000000005
17
Jayne Smith-Palmer, Karin Cerri, William Valentine. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsBMC Infectious Diseases 2015; 15(1) doi: 10.1186/s12879-015-0748-8
18
Maria Pleguezuelo, Laura Marelli, Sergio Maimone, Pinelopi Manousou, Elias Xirouchakis, Andrew K. Burroughs. Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?Current Hepatitis Reports 2008; 7(2): 72 doi: 10.1007/s11901-008-0011-5
19
Youngmin A. Lee, Scott L. Friedman. Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?Antiviral Research 2014; 107: 23 doi: 10.1016/j.antiviral.2014.03.012
20
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Expert Review of Anti-infective Therapy 2014; 12(7): 763 doi: 10.1586/14787210.2014.929497
21
Hellan Kwon, Anna S Lok. Does Antiviral Therapy Prevent Hepatocellular Carcinoma?Antiviral Therapy 2011; 16(6): 787 doi: 10.3851/IMP1895
22
Andrew Aronsohn, Donald Jensen. HCV Eradication: Implications for Disease ResolutionCurrent Hepatitis Reports 2011; 10(1): 27 doi: 10.1007/s11901-010-0076-9
23
Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosisThe Korean Journal of Hepatology 2011; 17(3): 220 doi: 10.3350/kjhep.2011.17.3.220
24
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infectionExpert Opinion on Investigational Drugs 2014; 23(5): 719 doi: 10.1517/13543784.2014.902049
25
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusExpert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
26
Andrea Messori, Brigitta Badiani, Sabrina Trippoli. Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome MeasuresClinical Drug Investigation 2015; 35(12): 843 doi: 10.1007/s40261-015-0338-y
27
Andrew Aronsohn, Nancy Reau. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV PatientsJournal of Clinical Gastroenterology 2009; 43(7): 661 doi: 10.1097/MCG.0b013e31819f66e2
28
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola, Guglielmo Borgia. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infectionExpert Review of Anti-infective Therapy 2014; 12(10): 1179 doi: 10.1586/14787210.2014.945432
29
Adriaan J. van der Meer, Jordan J. Feld, Harald Hofer, Piero L. Almasio, Vincenza Calvaruso, Conrado M. Fernández-Rodríguez, Soo Aleman, Nathalie Ganne-Carrié, Roberta D’Ambrosio, Stanislas Pol, Maria Trapero-Marugan, Raoel Maan, Ricardo Moreno-Otero, Vincent Mallet, Rolf Hultcrantz, Ola Weiland, Karoline Rutter, Vito Di Marco, Sonia Alonso, Savino Bruno, Massimo Colombo, Robert J. de Knegt, Bart J. Veldt, Bettina E. Hansen, Harry L.A. Janssen. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationJournal of Hepatology 2017; 66(3): 485 doi: 10.1016/j.jhep.2016.10.017
30
A. Striki, S. Manolakopoulos, M. Deutsch, M. Mela, M. Kalafateli, M. Schini, O. Anagnostou, C. Triantos, I. Andreadis, I. Ketikoglou, G. Papatheodoridis, D. Pectasides. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirinJournal of Viral Hepatitis 2014; 21(9): 624 doi: 10.1111/jvh.12197
31
Christoph R Werner, Carolin Franz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohortVirology Journal 2015; 12(1) doi: 10.1186/s12985-015-0261-0
32
David R. Nelson, Gary L. Davis, Ira Jacobson, Gregory T. Everson, Michael W. Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah Terrault, Nizar Zein. Hepatitis C Virus: A Critical Appraisal of Approaches to TherapyClinical Gastroenterology and Hepatology 2009; 7(4): 397 doi: 10.1016/j.cgh.2008.11.016
33
Shelagh M. Szabo, Jennifer C. Samp, David R. Walker, Suzanne Lane, Stephanie K. Cline, Katherine L. Gooch, Ricardo Jimenez-Mendez, Adrian R. Levy. Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic reviewAnnals of Hepatology 2015; 14(5): 618 doi: 10.1016/S1665-2681(19)30756-2
34
Akira Sato, Kayo Adachi, Toshiya Ishii, Masayo Yamaguchi, Mika Kobayashi, Mikihito Hayashi, Miyako Tabashi, Masahito Nomoto, Akira Nikai. A case of Child-Pugh class B cirrhosis in hepatitis C infection successfully treated with interferon beta after balloon-occluded retrograde transvenous obliteration for gastric varicesKanzo 2008; 49(7): 307 doi: 10.2957/kanzo.49.307
35
Ryota Higuchi, Hideki Yasuda, Keiji Koda, Masato Suzuki, Masato Yamazaki, Tohru Tezuka, Chihiro Kosugi, Atsushi Hirano, Shuichiro Uemura, Hironori Tsuchiya. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 2011; 36(1): 66 doi: 10.4030/jjcs.36.66
36
Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12World Journal of Gastroenterology 2016; 22(35): 8050-8059 doi: 10.3748/wjg.v22.i35.8050
37
R. Bielen, C. Moreno, H. Van Vlierberghe, S. Bourgeois, J.-P. Mulkay, T. Vanwolleghem, W. Verlinden, C. Brixco, J. Decaestecker, C. de Galocsy, F. Janssens, L. Van Overbeke, C. Van Steenkiste, F. D'Heygere, M. Cool, K. Wuyckens, F. Nevens, G. Robaeys. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experienceJournal of Viral Hepatitis 2017; 24(11): 976 doi: 10.1111/jvh.12726
38
B. L. Pearlman, N. Traub. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much MoreClinical Infectious Diseases 2011; 52(7): 889 doi: 10.1093/cid/cir076
39
Amit Singal, Jorge A. Marrero. Yamada' s Textbook of Gastroenterology2015; : 2146 doi: 10.1002/9781118512074.ch109
40
Nicolás Merchante, Antonio Rivero-Juárez, Francisco Téllez, Dolores Merino, María J Ríos-Villegas, Marina Villalobos, Mohamed Omar, Pilar Rincón, Antonio Rivero, Montserrat Pérez-Pérez, Miguel Raffo, Inmaculada López-Montesinos, Rosario Palacios, María A Gómez-Vidal, Juan Macías, Juan A Pineda, Nicolás Merchante, Pilar Rincón, María Iglesias, Luis M Real, Juan Macías, Juan A Pineda, Antonio Rivero Juárez, Teresa Brieva, Angela Camacho Espejo, Antonio Rivero, Francisco Téllez, Dolores Merino, Miguel Raffo, María J Ríos Villegas, Inmaculada López Montesinos, Marina Villalobos, Rosario Palacios, Jesús Santos, Mohamed Omar, Maria A Gómez Vidal, Monserrat Pérez Pérez. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosisJournal of Antimicrobial Chemotherapy 2018; 73(9): 2435 doi: 10.1093/jac/dky234
41
Aaron Cohn, Andrew Aronsohn. HCV Therapy: Treat now or wait?Current Hepatitis Reports 2013; 12(1): 7 doi: 10.1007/s11901-013-0163-9
42
Nicolás Merchante, Francisco Rodríguez-Arrondo, Boris Revollo, Esperanza Merino, Sofía Ibarra, María J. Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Francisco Téllez, Marcial Delgado-Fernández, María J. Ríos-Villegas, María A. García, Francisco J. Vera-Méndez, Guillermo Ojeda-Burgos, Miguel A. López-Ruz, Luis Metola, Mohamed Omar, María Remedios Alemán-Valls, Koldo Aguirrebengoa, Joseba Portu, Miguel Raffo, Juan Macías, Juan A. Pineda. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patientsAIDS 2018; 32(11): 1423 doi: 10.1097/QAD.0000000000001809
43
Soo Aleman, Nogol Rahbin, Ola Weiland, Loa Davidsdottir, Magnus Hedenstierna, Nina Rose, Hans Verbaan, Per Stål, Tony Carlsson, Hans Norrgren, Anders Ekbom, Fredrik Granath, Rolf Hultcrantz. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver CirrhosisClinical Infectious Diseases 2013; 57(2): 230 doi: 10.1093/cid/cit234
44
Andrew J. Muir. Understanding the Complexities of CirrhosisClinical Therapeutics 2015; 37(8): 1822 doi: 10.1016/j.clinthera.2015.05.507
45
Gamal Esmat, Maissa El Raziky. Cirrhosis: A practical guide to management2015; : 274 doi: 10.1002/9781118412640.ch24
46
Gisèle Nkontchou, Mounir Aout, Amel Mahmoudi, Dominique Roulot, Valérie Bourcier, Véronique Grando-Lemaire, Nathalie Ganne-Carrie, Jean-Claude Trinchet, Eric Vicaut, Michel Beaugrand. Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated CirrhosisCancer Prevention Research 2012; 5(8): 1007 doi: 10.1158/1940-6207.CAPR-11-0450
47
Ashwani K. Singal, Amanpal Singh, Sathya Jaganmohan, Praveen Guturu, Rajasekhara Mummadi, Yong–Fang Kuo, Gagan K. Sood. Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related CirrhosisClinical Gastroenterology and Hepatology 2010; 8(2): 192 doi: 10.1016/j.cgh.2009.10.026
48
Lars Haukali Omland, Peer Brehm Christensen, Henrik Krarup, Peter Jepsen, Nina Weis, Henrik Toft Sørensen, Niels Obel, Heiner Wedemeyer. Mortality among Patients with Cleared Hepatitis C Virus Infection Compared to the General Population: A Danish Nationwide Cohort StudyPLoS ONE 2011; 6(7): e22476 doi: 10.1371/journal.pone.0022476
49
Angelo Alves de Mattos, Ângelo Zambam de Mattos. Treatment of HCV infection in patients with cirrhosisAnnals of Hepatology 2010; 9: S80 doi: 10.1016/S1665-2681(19)31729-6
50
Chang Seok Bang, Il Han Song. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysisBMC Gastroenterology 2017; 17(1) doi: 10.1186/s12876-017-0606-9
51
Paulo R. Lerias de Almeida, Angelo Alves de Mattos, Cristiane Valle Tovo. Sustained virological response according to the type of early virological response in HCV and HCV/HIVAnnals of Hepatology 2010; 9(2): 150 doi: 10.1016/S1665-2681(19)31653-9
52
Ivan Gentile, Guglielmo Borgia. Surrogate endpoints and non-inferiority trials in chronic viral hepatitisJournal of Hepatology 2010; 52(5): 778 doi: 10.1016/j.jhep.2009.12.023
53
Angelo Iacobellis, Francesco Perri, Maria Rosa Valvano, Nazario Caruso, Grazia Anna Niro, Angelo Andriulli. Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated CirrhosisClinical Gastroenterology and Hepatology 2011; 9(3): 249 doi: 10.1016/j.cgh.2010.10.036
54
Ivan Gentile, Maria Aurora Carleo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virusExpert Opinion on Investigational Drugs 2010; 19(1): 151 doi: 10.1517/13543780903501505
55
Fabio Salvatore Macaluso, Vincenza Calvaruso, Antonio Craxì. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eyeFuture Microbiology 2015; 10(6): 977 doi: 10.2217/fmb.15.31
56
Mario Frías, Antonio Rivero-Juárez, Isabel Machuca, Ángela Camacho, Antonio Rivero. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunitiesExpert Review of Precision Medicine and Drug Development 2020; 5(4): 253 doi: 10.1080/23808993.2020.1764346
57
Serda Gulsun, Recep Tekin, Fatma Bozkurt. Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective AnalysisHepatitis Monthly 2011; 11(9): 731 doi: 10.5812/kowsar.1735143X.2462
58
Gennaro D’Amico, Giovanni Perricone. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?Current Hepatology Reports 2019; 18(2): 144 doi: 10.1007/s11901-019-00473-1
59
Tatsuo Kanda, Osamu Yokosuka, Masao Omata. Treatment of hepatitis C virus infection in the futureClinical and Translational Medicine 2013; 2(1) doi: 10.1186/2001-1326-2-9
60
Xiuzhu Gao, Mengru Zhan, Liquan Wang, Yanhua Ding, Junqi Niu. <p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>Journal of Hepatocellular Carcinoma 2020; : 347 doi: 10.2147/JHC.S279657
61
Katsuhisa Nakatsuka, Masanori Atsukawa, Masumi Shimizu, Hidemi Takahashi, Chiaki Kawamoto. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominanceWorld Journal of Hepatology 2015; 7(25): 2590-2596 doi: 10.4254/wjh.v7.i25.2590
62
X. Wang, F. Gao, G. Yuan, K. Shi, Y. Huang, Y. Chen, R. Qiu, L. Sun, J. Liu, C. Hu, Y. Zhou. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapyJournal of Viral Hepatitis 2016; 23(12): 971 doi: 10.1111/jvh.12574